

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. ***(previously presented)*** A method for treating or preventing vasomotor symptoms in a subject in need thereof, comprising the step of:

administering to said subject a composition, comprising:

a therapeutically effective amount of at least one norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof;

wherein said norepinephrine reuptake inhibitor is selected from the group consisting of: maprotiline; norpramine, desipramine; nisoxetine; atomoxetine; amoxapine; doxepin; lofepramine; amitriptyline; 1-[1-(3-fluorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[2-(4-methyl-1-piperazinyl)-1-[3-(trifluoromethyl)-phenyl]ethyl] cyclohexanol; 1-[1-(4-methoxy phenyl)-2-[4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-[4-(3-chlorophenyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-phenyl methyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[2-(3-chloro phenyl)-1-piperazinyl]-1-[3-methoxyphenyl)ethyl]cyclohexanol; 1-[2-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-1-[3-methoxyphenyl)ethyl]cyclohexanol; 1-[2-[4-(phenylmethyl)]-1-piperazinyl]-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)-phenyl]-1-piperazinyl]ethyl] cyclohexanol; 1-[1-(4-fluorophenyl)-2-[4-(phenylmethyl)-1-piperazinyl] ethyl] cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)-phenyl]-1-piperazinyl]ethyl]cyclopentanol; 1-[1-(4-fluorophenyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(3-trifluoromethyl phenyl)ethyl]cyclohexanol; 1-[1-(3-fluorophenyl)-2-(4-methyl-1-piperazinyl) ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl] cyclohexanol; 1-[2-dimethylamino)-1-(3-trifluoromethylphenyl) ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-piperazin-1-yl-

ethyl]-cyclohexanol; and combinations and pharmaceutically acceptable salts thereof.

2. *(original)* A method according to claim 1,
wherein said compound has a selectivity ratio of SERT:NET of less than about 1,000:1.
3. *(original)* A method according to claim 1,
wherein said compound has a selectivity ratio of SERT:NET of greater than about 2:1.
4. *(original)* A method according to claim 1,
wherein said compound has a selectivity ratio of SERT:NET of greater than about 5:1.
5. *(original)* A method according to claim 1,
wherein said compound has a selectivity ratio of SERT:NET of greater than about 10:1.
6. *(canceled)*
7. *(previously presented)* A method according to claim 1,
wherein said norepinephrine reuptake inhibitor is desipramine or pharmaceutically acceptable salt thereof.
8. *(withdrawn)* A method according to claim 1,
wherein said norepinephrine reuptake inhibitor is 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol or pharmaceutically acceptable salt thereof.
9. *(withdrawn)* A method according to claim 8,

wherein said norepinephrine reuptake inhibitor is a pure enantiomer of 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol.

10. **(original)** A method according to claim 1,
wherein said composition further comprises a therapeutically effective amount of at least one serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof.
11. **(original)** A method according to claim 10,
wherein said serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, paroxetine, sertraline, fluvoxamine, and combinations and pharmaceutically acceptable salts thereof.
12. **(original)** A method according to claim 10,
wherein said norepinephrine reuptake inhibitor and said serotonin reuptake inhibitor are administered concurrently.
13. **(original)** A method according to claim 1,
wherein said composition further comprises a therapeutically effective amount of at least one adrenergic _{α_2} receptor antagonist or a pharmaceutically acceptable salt thereof.
14. **(original)** A method according to claim 13,
wherein said norepinephrine reuptake inhibitor and said adrenergic _{α_2} receptor antagonist are administered concurrently.
15. **(original)** A method according to claim 13,
wherein said norepinephrine reuptake inhibitor and said adrenergic _{α_2} receptor antagonist are administered simultaneously.

16. *(cancelled)*

17. *(original)* A method according to claim 13,

wherein said adrenergic α_2 receptor antagonist is a compound selected from the group consisting of atipamezole; 2-[2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride (ARC 239 dihydrochloride); 2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole maleate (BRL 44408 maleate); BRL48962; BRL41992; SKF 104856; SKF 104078; MK912; 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro-1H-imidazole hydrochloride (efaroxan hydrochloride); 2-(1,4-benzodioxan-2-yl)-2-imidazoline hydrochloride (idazoxan hydrochloride); 2-(1-ethyl-2-indazolyl)methyl-1,4-benzodioxan hydrochloride (imiloxan hydrochloride); 17 α -hydroxy-20 α -yohimban-16 β -carboxylic acid, methyl ester hydrochloride (rauwolscine hydrochloride); (8 α R,12 α S,13 α S)-5,8,8 α ,9,10,11,12,12 α ,13,13 α -dehydro-3-methoxy-12-(ethylsulfonyl)-6H-isoquino[2,1- γ][1,6]naphthyridine hydrochloride (RS 79948 hydrochloride); 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole hydrochloride (RX 821002 hydrochloride); 8-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one (spiroxatrine); 17 α -hydroxyyohimban-16 α -carboxylic acid methyl ester hydrochloride (yohimbine hydrochloride); and combinations and pharmaceutically acceptable salts thereof.

18. *(original)* A method according to claim 13,

wherein said adrenergic α_2 receptor antagonist is selective for the adrenergic α_{2A} receptor.

19. *(original)* A method according to claim 13,

wherein said adrenergic α_2 receptor antagonist is selective for the adrenergic α_{2B} receptor.

20. *(original)* A method according to claim 13,
wherein said adrenergic α_2 receptor antagonist is selective for the adrenergic α_{2C} receptor.

21. *(original)* A method according to claim 13,
wherein said adrenergic α_2 receptor antagonist is selective for the adrenergic α_{2D} receptor.

22. *(original)* A method according to claim 1,
wherein said pharmaceutically acceptable salt is an acid addition salt.

23. *(original)* A method according to claim 1,
wherein said vasomotor symptom is the exhibition of vasomotor symptoms.

24. *(original)* A method according to claim 1,
wherein said subject is human.

25. *(original)* A method according to claim 24,
wherein said human is a female.

26. *(original)* A method according to claim 25,
wherein said female is pre-menopausal.

27. *(original)* A method according to claim 25,
wherein said female is peri-menopausal.

28. *(original)* A method according to claim 25,
wherein said female is post-menopausal.
29. *(original)* A method according to claim 24,
wherein said human is a male.
30. *(original)* A method according to claim 29,
wherein said male is naturally, chemically or surgically andropausal.
31. *(withdrawn)* A pharmaceutical composition, comprising:
- a. at least one norepinephrine reuptake inhibitor selected from the group consisting of maprotiline; reboxetine; norpramine, nisoxetine; atomoxetine; amoxapine; doxepin; lofepramin; amitriptyline; 1-[1-(3-fluorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl) ethyl]cyclohexanol; 1-[2-(4-methyl-1-piperazinyl)-1-[3-(trifluoromethyl)-phenyl]ethyl] cyclohexanol; 1-[1-(4-methoxy phenyl)-2-[4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-[4-(3-chlorophenyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-phenyl methyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[2-(3-chloro phenyl)1-piperazinyl]-1-[3-methoxyphenyl)ethyl]cyclohexanol; 1-[2-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-1-[3-methoxyphenyl)ethyl]cyclohexanol; 1-[2-[4-(phenyl methyl)-1-piperazinyl]-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoro methyl)-phenyl]-1-piperazinyl]ethyl] cyclohexanol; 1-[1-(4-fluorophenyl)-2-[4-(phenylmethyl)-1-piperazinyl] ethyl] cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)-phenyl]-1-piperazinyl]ethyl]cyclopentanol; 1-[1-(4-fluorophenyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(3-trifluoromethyl phenyl)ethyl]cyclohexanol; 1-[1-(3-fluorophenyl)-2-(4-methyl-1-piperazinyl)

ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl]
cyclohexanol; 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol;
1-[2-dimethylamino)-1-(3-trifluoromethylphenyl)ethyl]cyclohexanol; 1-[1-(3-
chlorophenyl)-2-piperazin-1-yl-ethyl]-cyclohexanol; and combinations and
pharmaceutically acceptable salts thereof;

- b. at least one serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof; and
- c. at least one pharmaceutically acceptable carrier.

32. **(withdrawn)** A pharmaceutical composition according to claim 31,
wherein said pharmaceutically acceptable salt is an acid addition salt.

33. **(canceled)**

34. **(canceled)**

35. **(withdrawn)** A pharmaceutical composition according to claim 31,
wherein said norepinephrine reuptake inhibitor is 1-[1-(3-chlorophenyl)-2-(4-
methyl-1-piperazinyl)ethyl]cyclohexanol.

36. **(withdrawn)** A pharmaceutical composition according to claim 35,
wherein said norepinephrine reuptake inhibitor is a pure enantiomer of 1-[1-
(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol.

37. **(withdrawn)** A pharmaceutical composition according to claim 31,
wherein said serotonin reuptake inhibitor is selected from the group consisting
of fluoxetine, paroxetine, sertraline, fluvoxamine, and combinations and
pharmaceutically acceptable salts thereof.

38. (*withdrawn*) A pharmaceutical composition, comprising:

- a. at least one norepinephrine reuptake inhibitor selected from the group consisting of maprotiline; reboxetine; norpramine, nisoxetine; atomoxetine; amoxapine; doxepin; lofepramine; amitriptyline; 1-[1-(3-fluorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[2-(4-methyl-1-piperazinyl)-1-[3-(trifluoromethyl)-phenyl]ethyl]cyclohexanol; 1-[1-(4-methoxyphenyl)-2-[4-methyl-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-[4-(3-chlorophenyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-phenylmethyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[2-(3-chlorophenyl)-1-piperazinyl]-1-[3-methoxyphenyl]ethyl]cyclohexanol; 1-[2-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-1-[3-methoxyphenyl]ethyl]cyclohexanol; 1-[2-[4-(phenylmethyl)-1-piperazinyl]-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)-phenyl]-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(4-fluorophenyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)-phenyl]-1-piperazinyl]ethyl]cyclopentanol; 1-[1-(4-fluorophenyl)-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(3-trifluoromethylphenyl)ethyl]cyclohexanol; 1-[1-(3-fluorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol; 1-[2-(dimethylamino)-1-(3-trifluoromethylphenyl)ethyl]cyclohexanol; 1-[1-(3-chlorophenyl)-2-piperazin-1-yl-ethyl]-cyclohexanol; and combinations and pharmaceutically acceptable salts thereof;
- b. one adrenergic α_2 receptor antagonist selected from the group consisting of atipamezole; 2-[2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride (ARC 239 dihydrochloride); 2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isindole

maleate (BRL 44408 maleate); BRL48962; BRL41992; SKF 104856; SKF 104078; MK912; 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro-1H-imidazole hydrochloride (efaroxan hydrochloride); 2-(1,4-benzodioxan-2-yl)-2-imidazoline hydrochloride (idazoxan hydrochloride); 2-(1-ethyl-2-indazolyl)methyl-1,4-benzodioxan hydrochloride (imiloxan hydrochloride); 17 α -hydroxy-20 α -yohimban-16 β -carboxylic acid, methyl ester hydrochloride (rauwolscine hydrochloride); (8 α R,12 α S,13 α S)-5,8,8 α ,9,10,11,12,12 α ,13,13 α -dehydro-3-methoxy-12-(ethylsulfonyl)-6H-isoquino[2,1- γ][1,6]naphthyridine hydrochloride (RS 79948 hydrochloride); 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole hydrochloride (RX 821002 hydrochloride); 8-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one (spiroxatrine); 17 α -hydroxy-yohimban-16 α -carboxylic acid methyl ester hydrochloride (yohimbine hydrochloride); and combinations and pharmaceutically acceptable salts thereof; and

c. at least one pharmaceutically acceptable carrier.

39. *(withdrawn)* A pharmaceutical composition according to claim 38, wherein said pharmaceutically acceptable salt is an acid addition salt.

40. *(canceled)*

41. *(canceled)*

42. *(withdrawn)* A pharmaceutical composition according to claim 38, wherein said norepinephrine reuptake inhibitor is 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol.

43. *(withdrawn)* A pharmaceutical composition according to claim 42,

wherein said norepinephrine reuptake inhibitor is a pure enantiomer of 1-[1-(3-chlorophenyl)-2-(4-methyl-1-piperazinyl)ethyl]cyclohexanol.

44. *(canceled)*

45. *(withdrawn)* A pharmaceutical composition according to claim 38,
wherein said adrenergic _{α 2} receptor antagonist is selective for the adrenergic _{α 2A} receptor.

46. *(withdrawn)* A pharmaceutical composition according to claim 38,
wherein said adrenergic _{α 2} receptor antagonist is selective for the adrenergic _{α 2B} receptor.

47. *(withdrawn)* A pharmaceutical composition according to claim 38,
wherein said adrenergic _{α 2} receptor antagonist is selective for the adrenergic _{α 2C} receptor.

48. *(withdrawn)* A pharmaceutical composition according to claim 38,
wherein said adrenergic _{α 2} receptor antagonist is selective for the adrenergic _{α 2D} receptor.